Table 2 Clinical and CMR parameters of patients with ECV ≤ 44% or ECV>44%
Clinical and CMR parameters | All patients (n = 38) | Patients with ECV ≤ 44% (n = 22) | Patients with ECV>44% (n = 16) | P value |
|---|---|---|---|---|
Male(%) | 28(74%) | 15(68%) | 13(81%) | 0.669 |
Age(years) | 59 ± 11 | 56 ± 13 | 63 ± 6 | 0.172 |
NT-proBNP(pg/mL) | 950(418–3541) | 614(175–1354) | 3879(1245–11,415) | 0.003 |
Troponin T(ng/mL) | 0.034(0.014–0.053) | 0.024(0.012–0.037) | 0.050(0.035–0.060) | 0.008 |
dFLC (mg/L) | 167(93–272) | 149(51–192) | 290(129–969) | 0.019 |
Mayo stage | ||||
I | 8(21%) | 7(32%) | 1(6%) | 0.166 |
II | 11(29%) | 9(41%) | 2(13%) | 0.166 |
III | 10(26%) | 5(23%) | 5(31%) | 0.843 |
IV | 9(24%) | 1(4%) | 8(50%) | <0.001 |
Native T1 (ms) | 1399 ± 103 | 1342 ± 82 | 1479 ± 71 | <0.001 |
LVEDVi (mL/m2) | 72 ± 13 | 73 ± 15 | 71 ± 8 | 0.934 |
LVESVi (mL/m2) | 30 ± 3 | 29 ± 3 | 31 ± 3 | 0.402 |
LVEF (%) | 54 ± 9 | 58 ± 7 | 49 ± 8 | 0.007 |
LVMI (g/m2) | 117 ± 23 | 107 ± 23 | 132 ± 14 | 0.004 |
LVSV (mL) | 66 ± 13 | 73 ± 10 | 56 ± 11 | <0.001 |
Therapeutic method | ||||
Chemotherapy or ASCT | 23(61%) | 16(73%) | 7(44%) | 0.201 |
Expectant treatment | 15(39%) | 6(27%) | 9(56%) | 0.201 |